Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Lantern Pharma
(NASDAQ:LTRN)
Intraday
$5.2308
-0.1492
[-2.77%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$5.2308
-0.1492
[-2.77%]
Last update: 9:19AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Lantern Pharma Stock (NASDAQ:LTRN)
Lantern Pharma Stock (NASDAQ: LTRN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 25, 2024
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma
Benzinga Newsdesk
-
7 hours ago
Monday, April 22, 2024
Lantern Pharmashares are trading higher after the company was approved to expand its Harmonic clinical trial for non-small cell lung cancer in never-smokers into Japan and Taiwan.
Benzinga Newsdesk
-
3 days ago
Lantern Pharma Approved To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer In Never-Smokers Into Japan and Taiwan
Benzinga Newsdesk
-
3 days ago
Friday, April 19, 2024
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
6 days ago
Thursday, April 11, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Apr 11, 2024, 12:31PM
Tuesday, March 19, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Mar 19, 2024, 1:31PM
Lantern Pharma shares are trading lower. The company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 19, 2024, 11:58AM
Monday, March 18, 2024
Recap: Lantern Pharma Q4 Earnings
Benzinga Insights
-
Mar 18, 2024, 4:30PM
Lantern Pharma Q4 2023 GAAP EPS $(0.39) Beats $(0.48) Estimate
Benzinga Newsdesk
-
Mar 18, 2024, 4:26PM
Earnings Scheduled For March 18, 2024
Benzinga Insights
-
Mar 18, 2024, 5:57AM
Friday, March 15, 2024
Lantern Pharma Earnings Preview
Benzinga Insights
-
Mar 15, 2024, 11:00AM
Lantern Pharma Announces Initial Patients Dosed In First-In-Human Clinical Trial For AI-Guided Drug-Candidate, LP-284
Benzinga Newsdesk
-
Mar 15, 2024, 8:06AM
Monday, March 11, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Mar 11, 2024, 1:31PM
Friday, March 08, 2024
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Mar 8, 2024, 12:31PM
Wednesday, March 06, 2024
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Mar 6, 2024, 1:54PM
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Avi Kapoor
-
Mar 6, 2024, 11:45AM
Monday, March 04, 2024
Lantern Pharma's AI Platform, RADR, Surpasses 60B Data Points, Anticipates Reaching 100B Data Points In 2024, Paving The Way For Enhanced Cancer Therapy Innovations And Expedited Development Timelines
Benzinga Newsdesk
-
Mar 4, 2024, 8:05AM
Thursday, February 15, 2024
Lantern Pharma Advances ADC Program Across Multiple Solid Tumor Cancers
Benzinga Newsdesk
-
Feb 15, 2024, 8:07AM
Monday, December 18, 2023
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Dec 18, 2023, 8:08AM
Thursday, November 30, 2023
FDA Grants Lantern Pharma Orphan Drug Designation For Drug Candidate LP-284 In High-Grade B-cell Lymphomas
Benzinga Newsdesk
-
Nov 30, 2023, 8:12AM
Tuesday, November 28, 2023
Lantern Pharma Awarded Orphan Designation Status For "(+)N-hydroxy-N-(methylacylfulvene)urea" For The Treatment Of Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC And BCL2 Rearrangements
Benzinga Newsdesk
-
Nov 28, 2023, 9:50AM
Thursday, November 09, 2023
Lantern Pharma shares are trading higher after the company reported better-than-expected Q3 GAAP EPS results.
Benzinga Newsdesk
-
Nov 9, 2023, 1:14PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Nov 9, 2023, 12:31PM
Wednesday, November 08, 2023
Lantern Pharma: Q3 Earnings Insights
Benzinga Insights
-
Nov 8, 2023, 4:35PM
Lantern Pharma Q3 2023 Gaap EPS $(0.29) Beats $(0.45) Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 4:33PM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Tuesday, November 07, 2023
A Preview Of Lantern Pharma's Earnings
Benzinga Insights
-
Nov 7, 2023, 1:01PM
Tuesday, October 03, 2023
Lantern Pharma Announces Publication In Clinical Cancer Research Highlighting The Enhanced Efficacy Of LP-184 In Glioblastoma
Benzinga Newsdesk
-
Oct 3, 2023, 8:11AM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Tuesday, September 26, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 26, 2023, 12:04PM
Monday, September 25, 2023
Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For LP-184 in Advanced Solid Tumors
Benzinga Newsdesk
-
Sep 25, 2023, 8:32AM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Monday, September 18, 2023
Lantern Pharma Receives IND Clearance From FDA Enabling Phase 1 Initiation For Drug Candidate LP-284 In Non-Hodgkin's Lymphomas
Benzinga Newsdesk
-
Sep 18, 2023, 9:03AM
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 15, 2023, 11:52AM
Monday, August 28, 2023
Lantern Pharma Announced A Substantial Increase In The Power And Capabilities Of RADR Focused On Improving The Drug Development Process For Immune Checkpoint Inhibitors
Benzinga Newsdesk
-
Aug 28, 2023, 8:02AM
Monday, August 14, 2023
Lantern Pharma Receives Notice Of U.S. Patent Allowance For Drug Candidate LP-184 For The Treatment Of Rare Pediatric Brain Cancer, ATRT
Happy Mohamed
-
Aug 14, 2023, 9:02AM
Thursday, August 10, 2023
Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation
Happy Mohamed
-
Aug 10, 2023, 12:15PM
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 7:16AM
Wednesday, August 09, 2023
Lantern Pharma Q2 EPS $(0.44) Misses $(0.43) Estimate
Benzinga Newsdesk
-
Aug 9, 2023, 4:18PM
Earnings Scheduled For August 9, 2023
Benzinga Insights
-
Aug 9, 2023, 4:54AM
Tuesday, July 18, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Jul 18, 2023, 9:06AM
Monday, June 26, 2023
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target
Benzinga Newsdesk
-
Jun 26, 2023, 2:37PM
Oncotarget Publishes New Data By Lantern Pharma, An AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement Of LP-284, A Novel Synthetically Lethal Drug Candidate For Non-Hodgkin's Lymphomas
Happy Mohamed
-
Jun 26, 2023, 8:30AM
Monday, June 12, 2023
Lantern Pharma Secures FDA Clearance Of IND Application For Drug Candidate LP-184 In Solid Tumors
Benzinga Newsdesk
-
Jun 12, 2023, 8:31AM
Thursday, June 08, 2023
Lantern Pharma Leverages AI Platform, RADR, To Develop Breakthrough Antibody Drug Conjugates In Collaboration With Bielefeld University
Happy Mohamed
-
Jun 8, 2023, 9:02AM
Thursday, May 25, 2023
EF Hutton Assumes Lantern Pharma at Buy, Maintains Price Target of $11
Benzinga Newsdesk
-
May 25, 2023, 8:26AM
Thursday, May 18, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights
-
May 18, 2023, 11:00AM
HC Wainwright & Co. Initiates Coverage On Lantern Pharma with Neutral Rating
Benzinga Newsdesk
-
May 18, 2023, 6:25AM
Tuesday, May 09, 2023
Lantern Pharma Q1 EPS $(0.36) Beats $(0.48) Estimate
Benzinga Newsdesk
-
May 9, 2023, 4:15PM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch